We would like to thank Dr. Scott Berry for providing live tweets from the ECCO-ESMO 2011 conference.

 

mCRC 3rd Line - tumours with PG13D mutations - results presented today divergent from cetuximab data shopping these patients may benefit from anti EGFR tx #emcc2011 #colorectalcancer

 

Personalized Medicine Late Breaking Abstract - KRAS mutation outcome analysis of 3 large Pmab trials in colorectal ca - #emcc2011 #colorectalcancer

KRAS mutation outcomes with Pmab in colorectal cancer OS - no individual mutant consistently assoc'd with pfs/os outcomes #emcc2011 #colorectalcancer

KRAS mutation analysis in mCRC treated with Pmab - tumours with PG13D mutations - no response in single agent 3rd Line trial #emcc2011 #colorectalcancer

RESPECT trial 1st line mCRC FOLFOX +/- Sorafenib N=198: Primary Endpt PFS - no difference #emcc2011 #colorectalcancer

RESPECT trial 1st line mCRC FOLFOX +/- Sorafenib N=198: RR higher in placebo arm #emcc2011 #colorectalcancer

RESPECT trial 1st line mCRC FOLFOX +/- Sorafenib KRAS analysis ongoing but no differences seen so far in KRAS WT vs mutant #emcc2011 #colorectalcancer

RESPECT trial 1st line mCRC FOLFOX +/- Sorafenib - increased toxicity and no OS benefit in Sorafenib arm #emcc2011 #colorectalcancer

PICCOLO - 2nd line mCRC - Ir vs Ir+Pmab - No improvement in OS in large phase III trial #emcc2011 #colorectalcancer

PICCOLO - in KRAS WT patients : 29% had one of : BRAF/NRAS/PIK3CA/KRAS146 mutations - no benefit or harmed by Pmab

PICCOLO - in KRAS WT patients : 29% had one of : BRAF/NRAS/PIK3CA/KRAS146 mutations - no benefit or harmed by Pmab #emcc2011

PICCOLO - 2nd line mCRC Ir +/- Pmab - RR and PFS Benefit - but no OS benefit seen in subset of patients with tumours that had no mutations

TAS 102 - new inhibitor of thymidylate synthetase and DNA synthesis - randomized phase 2 trial of this agent vs NSC in chemorefractory mCRC patients demonstrates 2.4 mos OS benefit (HR = 0.56) #emcc2011

TAS 102 - KRAS mutant subgroup - 4.1 mos OS benefit (13 vs 6.9 mos) HR=0.44 - PI Dr Kuboki states confirmatory Phase III trial needed #emcc2011

TAS 102 - full update on oncologyeducation.com ECCO/ESMO 2011 meeting update coming soon #emcc2011

TAS 102 : survival benefit seen with this new chemotheraputic agent in chemorefractory mCRC in rand phase II study #emcc2011